	US 12,286,626 B2
	Myocardial enhancer RNA and methods of use
Ching-Pin Chang, Indianapolis, IN (US); and Wei Cheng, Indianapolis, IN (US)
Assigned to THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
Appl. No. 17/283,845
Filed by THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
PCT Filed Oct. 18, 2019, PCT No. PCT/US2019/056995 § 371(c)(1), (2) Date Apr. 8, 2021, PCT Pub. No. WO2020/081972, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,732, filed on Oct. 19, 2018.
Prior Publication US 2021/0380977 A1, Dec. 9, 2021
Int. Cl. C12N 15/113 (2010.01); C12Q 1/6883 (2018.01)

CPC C12N 15/113 (2013.01) [C12Q 1/6883 (2013.01); C12N 2310/14 (2013.01)]

16 Claims

1. A method of treating a patient at risk for heart disease comprising:

administering a therapeutically effective amount of an RNA sequence to the patient, wherein the RNA sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO: 2 or its corresponding DNA equivalent thereof.